Pharmacogenomics – a minor rather than major force in clinical medicine

References

• Polasek T. Drugs and genetics. Aust Prescr. 2017 Oct;40(5):167. doi: 10.18773/austprescr.2017.061
   PubMedGoogle Scholar
• Polasek TM, Mina K, Suthers G. Pharmacogenomics in general practice - the time has come. Aust J Gen Pract. 2019;48(3):100–105. doi: 10.31128/AJGP-10-18-4733
   PubMed Web of Science ®Google Scholar
• Suthers GK, Polasek TM. Letter to the editor: reply to Bousman et al. Pharmacogenomics. 2019;20(15):1061–1062. doi: 10.2217/pgs-2019-0110
   PubMed Web of Science ®Google Scholar
• Polasek T, Caramins M, Suthers G. Regulatory and other responses to the pharmaceutical opioid problem. Med J Aust. 2019 Sep;211(5):237–237 e1. doi: 10.5694/mja2.50297
   PubMedGoogle Scholar
• Polasek TM. Calculation of the pharmacogenomics benefit score for patients with medication-related problems. Front Genet. 2023;14:14.
   Web of Science ®Google Scholar
• Polasek TM, Mostafa S, Kirkpatrick CMJ. Consistent terminology for medication-related problems in pharmacogenomic cases. J Psychiatry Neurosci. 2023 May;48(3):E151–E152. doi: 10.1503/jpn.230022-l
   PubMed Web of Science ®Google Scholar
• Mostafa S, Polasek TM, Bousman C, et al. Pharmacogenomics in psychiatry - the challenge of cytochrome P450 enzyme phenoconversion and solutions to assist precision dosing. Pharmacogenomics. 2022;23(15):857–867. doi: 10.2217/pgs-2022-0104
   PubMed Web of Science ®Google Scholar
• Peck RW, Shahin MH, Vinks AA. Precision dosing: the clinical pharmacology of goldilocks. Clin Pharmacol Ther. 2021 Jan;109(1):11–14. doi: 10.1002/cpt.2112
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Fujita M. Whole genome sequencing analysis for cancer genomics and precision medicine. Cancer Sci. 2018 Mar;109(3):513–522. doi: 10.1111/cas.13505
   PubMed Web of Science ®Google Scholar
• Wise AL, Manolio TA, Mensah GA, et al. Genomic medicine for undiagnosed diseases. Lancet. 2019 Aug 10;394(10197):533–540. doi: 10.1016/S0140-6736(19)31274-7
   PubMed Web of Science ®Google Scholar
• Polasek TM, Ambler K, Scott HS, et al. Targeted pharmacotherapy after somatic cancer mutation screening. F1000Res. 2016;5:1551. doi: 10.12688/f1000research.9040.1
   PubMedGoogle Scholar
• Peck RW. Precision medicine is not just genomics: the right dose for every patient. Annu Rev Pharmacol Toxicol. 2018 Jan 6;58(1):105–122. doi: 10.1146/annurev-pharmtox-010617-052446
   PubMedGoogle Scholar
• Kloypan C, Koomdee N, Satapornpong P, et al. A comprehensive review of HLA and severe cutaneous adverse drug reactions: implication for clinical pharmacogenomics and precision medicine. Pharmaceuticals (Basel). 2021 Oct 25;14(11):1077. doi: 10.3390/ph14111077
   PubMedGoogle Scholar
• Manson LEN, Swen JJ, Guchelaar HJ. Diagnostic test criteria for HLA genotyping to prevent drug hypersensitivity reactions: a systematic review of actionable HLA recommendations in CPIC and DPWG guidelines. Front Pharmacol. 2020;11:567048. doi: 10.3389/fphar.2020.567048
   PubMed Web of Science ®Google Scholar
• Stojanova J, Day RO, Suthers G. Avoiding severe drug hypersensitivity reactions: a case for HLA genotyping for at-risk patients. Med J Aust. 2023 Jun 5;218(10):441–444.
   PubMed Web of Science ®Google Scholar
• Lindh M, Hallberg P, Yue QY, et al. Clinical factors predicting drug-induced liver injury due to flucloxacillin. Drug Healthc Patient Saf. 2018;10:95–101. doi: 10.2147/DHPS.S178394
   PubMed Web of Science ®Google Scholar
• Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017 Oct;17(5):395–402. doi: 10.1038/tpj.2017.21
   PubMed Web of Science ®Google Scholar
• Caudle KE, Hoffman JM, Gammal RS. Pharmacogenomics implementation: “a little less conversion a little more action, please”. Pharmacogenomics. 2023;24(4):183–186. doi: 10.2217/pgs-2023-0020
   PubMedGoogle Scholar
• Dias MM, Sorich MJ, Rowland A, et al. The routine clinical use of pharmacogenetic tests: what it will require? Pharm Res. 2017 Aug;34(8):1544–1550. doi: 10.1007/s11095-017-2128-0
   PubMed Web of Science ®Google Scholar
• Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018 Feb;103(2):210–216.
   PubMed Web of Science ®Google Scholar
• Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011 Mar;89(3):464–467. doi: 10.1038/clpt.2010.279
   PubMed Web of Science ®Google Scholar
• Malki MA, Pearson ER. Drug-drug-gene interactions and adverse drug reactions. Pharmacogenomics J. 2020 Jun;20(3):355–366. doi: 10.1038/s41397-019-0122-0
   PubMed Web of Science ®Google Scholar
• Achour B, Gosselin P, Terrier J, et al. Liquid biopsy for patient characterization in cardiovascular disease: verification against markers of cytochrome P450 and P-Glycoprotein activities. Clin Pharmacol Ther. 2022 Jun;111(6):1268–1277.
   PubMed Web of Science ®Google Scholar
• Polasek TM, Schuck V. Improving the efficiency of clinical pharmacology studies. Clin Pharmacol Drug Dev. 2023 Jun 23;12(8):771–774.
   PubMed Web of Science ®Google Scholar
• Mostafa S, Polasek TM, Bousman C, et al. Delineating gene-environment effects using virtual twins of patients treated with clozapine. CPT Pharmacometrics Syst Pharmacol. 2023 Feb;12(2):168–179.
   PubMedGoogle Scholar
• Angehrn Z, Haldna L, Zandvliet AS, et al. Artificial intelligence and machine learning applied at the point of care. Front Pharmacol. 2020;11:11. doi: 10.3389/fphar.2020.00759
   PubMed Web of Science ®Google Scholar
• Santini C, Schindler E, Attig J, et al., editors. Development of a quantitative systems pharmacology model for clinical dose and schedule optimization of forimtamig, a T cell engaging antibody targeting GPRC5D in multiple myeloma. American Association for Cancer Research Annual Meeting 2023; Orlando, Florida, USA; 2023.
   Google Scholar
• Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006;58(3):521–590. doi: 10.1124/pr.58.3.6
   PubMed Web of Science ®Google Scholar
• Polasek TM, Shakib S, Rostami-Hodjegan A. Precision dosing in clinical medicine: present and future. Expert Rev Clin Pharmacol. 2018 Aug;11(8):743–746. doi: 10.1080/17512433.2018.1501271
   PubMed Web of Science ®Google Scholar
• Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–5. doi: 10.1056/NEJMp1500523
   PubMed Web of Science ®Google Scholar
• Polasek TM, Kirkpatrick CMJ, Rostami-Hodjegan A. Precision dosing to avoid adverse drug reactions. Ther Adv Drug Saf. 2019;10:2042098619894147. doi: 10.1177/2042098619894147
   Web of Science ®Google Scholar
• Polasek TM, Shakib S, Rostami-Hodjegan A. Precision medicine technology reality not hype - the example of model-informed precision dosing. F1000Res. 2019;8:1709. doi: 10.12688/f1000research.20489.2
   PubMedGoogle Scholar
• Polasek TM, Rostami-Hodjegan A. Virtual twins: understanding the data required for model-informed precision dosing. Clin Pharmacol Ther. 2020 Feb 14;107(4):742–745. doi: 10.1002/cpt.1778
   PubMed Web of Science ®Google Scholar
• Darwich AS, Polasek TM, Aronson JK, et al. Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61(1):225–245. doi: 10.1146/annurev-pharmtox-033020-113257
   PubMed Web of Science ®Google Scholar
• Gonzalez D, Rao GG, Bailey SC, et al. Precision dosing: public health need, proposed framework, and anticipated impact. Clin Transl Sci. 2017 Nov;10(6):443–454.
   PubMed Web of Science ®Google Scholar
• Darwich AS, Ogungbenro K, Vinks AA, et al. Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. Clin Pharmacol Ther. 2017 May;101(5):646–656.
   PubMed Web of Science ®Google Scholar
• Hopkins AM, Menz BD, Wiese MD, et al. Nuances to precision dosing strategies of targeted cancer medicines. Pharmacol Res Perspect. 2020 Aug;8(4):e00625.
   PubMed Web of Science ®Google Scholar
• Girirajan S, Eichler EE. Phenotypic variability and genetic susceptibility to genomic disorders. Hum Mol Genet. 2010 Oct 15;19(R2):R176–87.
   PubMedGoogle Scholar
• Shon JH, Yoon YR, Kim KA, et al. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics. 2002;12(2):111–119. doi: 10.1097/00008571-200203000-00005
   PubMedGoogle Scholar
• Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet. 2001;40(8):587–603. doi: 10.2165/00003088-200140080-00003
   PubMed Web of Science ®Google Scholar
• Payan M, Rouini MR, Tajik N, et al. Hydroxylation index of omprazole in relation to CYP2C19 polymophism and sex in a healthy Iranian population. DARU J Pharm Sci. 2014;22(81). doi: 10.1186/s40199-014-0081-6
   Google Scholar
• Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug target, and side effects. N Engl J Med. 2003;348(6):538–549. doi: 10.1056/NEJMra020526
   PubMed Web of Science ®Google Scholar
• Meloche M, Leclair G, Jutras M, et al. Leveraging large observational studies to discover genetic determinants of drug concentrations: a proof-of-concept study. Clin Transl Sci. 2022 Apr;15(4):1063–1073.
   PubMed Web of Science ®Google Scholar
• Furman KD, Grimm DR, Mueller T, et al. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. Pharmacogenetics. 2004;14(5):279–284. doi: 10.1097/00008571-200405000-00002
   PubMedGoogle Scholar
• Brown LC, Stanton JD, Bharthi K, et al. Pharmacogenomic testing and depressive symptom remission: a systematic review and meta-analysis of prospective, controlled clinical trials. Clin Pharmacol Ther. 2022 Dec;112(6):1303–1317. doi: 10.1002/cpt.2748
   PubMed Web of Science ®Google Scholar
• Swen JJ, van der Wouden CH, Manson LE, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023 Feb 4;401(10374):347–356. doi: 10.1016/S0140-6736(22)01841-4
   PubMed Web of Science ®Google Scholar
• Rogers A, Mackenzie IS, MacDonald TM, et al. The PREPARE study: benefits of pharmacogenetic testing are unclear. Lancet. 2023 Jun 3;401(10391):1850. doi: 10.1016/S0140-6736(23)00853-X
   PubMedGoogle Scholar
• Peñas-LLedó E, LLerena A. Clinical use of pre-emptive pharmacogenetic programmes. Lancet. 2023 Feb 4;401(10374):320–321.
   PubMed Web of Science ®Google Scholar
• Thomas CD, Mosley SA, Kim S, et al. Examination of metoprolol pharmacokinetics and pharmacodynamics across CYP2D6 genotype-derived activity scores. CPT Pharmacometrics Syst Pharmacol. 2020 Dec;9(12):678–685.
   PubMedGoogle Scholar
• Brown JT, Bishop JR, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. Clin Pharmacol Ther. 2019 Jul;106(1):94–102.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Caudle KE, Gong L, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017 Sep;102(3):397–404.
   PubMed Web of Science ®Google Scholar
• Rayner CR, Smith PF, Andes D, et al. Model-informed drug development for anti-infectives: state of the art and future. Clin Pharmacol Ther. 2021 Apr;109(4):867–891.
   PubMed Web of Science ®Google Scholar
• Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014 Apr;95(4):376–82.
   PubMed Web of Science ®Google Scholar
• Crews KR, Monte AA, Huddart R, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther. 2021 Oct;110(4):888–896. doi: 10.1002/cpt.2149
   PubMed Web of Science ®Google Scholar
• Bousman CA, Maruf AA, Marques DF, et al. The emergence, implementation, and future growth of pharmacogenomics in psychiatry: a narrative review. Psychol Med. Sep 2023;29:1–11.
   Google Scholar
• Osteberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497. doi: 10.1056/NEJMra050100
   PubMed Web of Science ®Google Scholar
• Assawasuwannakit P, Braund R, Duffull SB. Quantification of the forgiveness of drugs to imperfect adherence. CPT Pharmacometrics Syst Pharmacol. 2015 Mar;4(3):e00004. doi: 10.1002/psp4.4
   PubMedGoogle Scholar
• Polasek TM, Rayner CR, Peck RW, et al. Toward dynamic prescribing information: codevelopment of companion model-informed precision dosing tools in drug development. Clin Pharmacol Drug Dev. 2019 May;8(4):418–425.
   PubMed Web of Science ®Google Scholar
• Polasek TM, Lin FKL, Miners JO, et al. Perpetrators of pharmacokinetic drug-drug interactions from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol. 2011;71(5):727–736. doi: 10.1111/j.1365-2125.2011.03903.x
   PubMed Web of Science ®Google Scholar
• Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018 Mar 31;391(10127):1263–1273. doi: 10.1016/S0140-6736(18)30475-6
   PubMed Web of Science ®Google Scholar
• Middleton PG, Mall MA, Drevinek P, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019 Nov 7;381(19):1809–1819. doi: 10.1056/NEJMoa1908639
   PubMed Web of Science ®Google Scholar
• Polasek TM, Doogue MP, Miners JO. Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1. Ther Adv Drug Saf. 2011 Dec;2(6):253–61. doi: 10.1177/2042098611422559
   PubMedGoogle Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with actue coronary syndromes. N Engl J Med. 2009;361(11):1045–1057. doi: 10.1056/NEJMoa0904327
   PubMed Web of Science ®Google Scholar
• Polasek TM. Beyond CYP2C19 - A New Chapter in Clopidogrel Pharmacogenomics. J Pharm Pract Res. 2011;41(1):14–16. doi: 10.1002/j.2055-2335.2011.tb00054.x
   Google Scholar
• Forbes HL, Polasek TM. Potential drug–drug interactions with direct oral anticoagulants in elderly hospitalized patients. Ther Adv Drug Saf. 2017;8(10):319–328. doi: 10.1177/2042098617719815
   PubMed Web of Science ®Google Scholar
• Maertens JA, Rahav G, Lee DG, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021 Feb 6;397(10273):499–509. doi: 10.1016/S0140-6736(21)00219-1
   PubMed Web of Science ®Google Scholar
• Roden DM, McLeod HL, Relling MV, et al. Pharmacogenomics. Lancet. 2019 Aug 10;394(10197):521–532. doi: 10.1016/S0140-6736(19)31276-0
   PubMed Web of Science ®Google Scholar
• Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nat Rev Genet. 2023 Jan 27;24(6):350–362.
   PubMed Web of Science ®Google Scholar
• Bally S, Cottin J, Gagnieu MC, et al. Publication bias in pharmacogenetics of adverse reaction to antiseizure drugs: an umbrella review and a meta-epidemiological study. PLoS One. 2022;17(12):e0278839. doi: 10.1371/journal.pone.0278839
   PubMed Web of Science ®Google Scholar
• Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharmacol Ther. 2011 May;89(5):662–673.
   PubMed Web of Science ®Google Scholar
• Mostafa S, Kirkpatrick CMJ, Byron K, et al. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes. J Neural Transm (Vienna). 2019 Jan;126(1):5–18.
   PubMed Web of Science ®Google Scholar
• Pritchard D, Patel JN, Stephens LE, et al. Comparison of FDA table of pharmacogenetic associations and clinical pharmacogenetics implementation consortium guidelines. Am J Health Syst Pharm. 2022 Jun 7;79(12):993–1005. doi: 10.1093/ajhp/zxac064
   PubMed Web of Science ®Google Scholar
• Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017 Jul;102(1):37–44.
   PubMed Web of Science ®Google Scholar
• Hinderer M, Boeker M, Wagner SA, et al. Integrating clinical decision support systems for pharmacogenomic testing into clinical routine - a scoping review of designs of user-system interactions in recent system development. BMC Med Inform Decis Mak. 2017 Jun 6;17(1):81. doi: 10.1186/s12911-017-0480-y
   PubMedGoogle Scholar
• Polasek TM, Rowland A, Wiese MD, et al. Pharmacists in Australian general practice: an opportunity for expertise in precision medicine. Ther Adv Drug Saf. 2015;6(5):186–188.
   PubMedGoogle Scholar
• Robson J. Screening in general practice and primary care. Br Med Bull. 1998;54(4):961–982. doi: 10.1093/oxfordjournals.bmb.a011741
   PubMed Web of Science ®Google Scholar
• Pearce A, Terrill B, Alffenaar JW, et al. Pharmacogenomic testing: perception of clinical utility, enablers and barriers to adoption in Australian hospitals. Intern Med J. 2022 Jul;52(7):1135–1143.
   PubMed Web of Science ®Google Scholar
• Stanek EJ, Sanders CL, Taber KA, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012 Mar;91(3):450–8.
   PubMed Web of Science ®Google Scholar
• Turner RM, Magavern EF, Pirmohamed M. Pharmacogenomics: Relevance and opportunities for clinical pharmacology. Br J Clin Pharmacol. 2022 Sep;88(9):3943–3946. doi: 10.1111/bcp.15329
   PubMed Web of Science ®Google Scholar
• Rothstein MA, Epps PG. Ethical and legal implications of pharmacogenomics. Nat Rev Genet. 2001 Mar;2(3):228–31. doi: 10.1038/35056075
   PubMed Web of Science ®Google Scholar
• Marchant G, Barnes M, Evans JP, et al. From genetics to genomics: facing the liability implications in clinical care. J Law Med Ethics. 2020 Mar;48(1):11–43.
   PubMed Web of Science ®Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2013 Jan 29;61(4):e78–e140. doi: 10.1016/j.jacc.2012.11.019
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Bittl JA, et al. ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2016 Sep 6;68(10):1082–1115. doi: 10.1016/j.jacc.2016.03.513
   PubMed Web of Science ®Google Scholar
• Luzum JA, Cheung JC. Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations. Pharmacogenomics. 2018;19(15):1203–1216. doi: 10.2217/pgs-2018-0097
   PubMed Web of Science ®Google Scholar
• Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019 Aug 1;30(8):1194–1220. doi: 10.1093/annonc/mdz173
   PubMed Web of Science ®Google Scholar
• Mulder TAM, de with M, Del Re M, et al. Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy. Cancers (Basel). 2021 Feb 12;13(4):771. doi: 10.3390/cancers13040771
   PubMed Web of Science ®Google Scholar
• Primorac D, Bach-Rojecky L, Vadunec D, et al. Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of big data. Pharmacogenomics. 2020;21(2):141–156. doi: 10.2217/pgs-2019-0134
   PubMed Web of Science ®Google Scholar
• Polasek TM. Virtual twin for healthcare management. Front Digit Health. 2023;5:1246659. doi: 10.3389/fdgth.2023.1246659
   PubMedGoogle Scholar
• Al-Sarawi F, Polasek TM, Caughey GE, et al. Prescribing errors and adverse drug reaction documentation before and after implementation of e-prescribing using the enterprise patient administration system. J Pharm Pract Res. 2019;49(1):27–32. doi: 10.1002/jppr.1454
   Google Scholar
• Dzau VJ, Ginsburg GS. Realizing the full potential of precision medicine in health and health care. JAMA. 2016 Oct 25;316(16):1659–1660.
   PubMed Web of Science ®Google Scholar
• Polasek TM, Leelasena I, Betscheider I, et al. Safety, tolerability, and pharmacokinetics of IMU-935, a novel inverse agonist of retinoic acid receptor-related orphan nuclear receptor gammat: results from a double-blind, placebo-controlled, first-in-human phase 1 study. Clin Pharmacol Drug Dev. 2023 May;12(5):525–534.
   PubMed Web of Science ®Google Scholar
• Lesko LJ, Woodcock J. Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J. 2002;2(1):20–4. doi: 10.1038/sj.tpj.6500046
   PubMedGoogle Scholar
• Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98(2):127–134. doi: 10.1002/cpt.147
   PubMed Web of Science ®Google Scholar